Wednesday June 19, 2019
Home Lead Story Billion-Dolla...

Billion-Dollar Business Goes To The Dog Walkers

Dog walking is billion-dollar industry

0
//
The results showed that the pups' attractiveness was lowest at birth and increased to a maximum before 10 weeks of age before declining and then levelling off.
Representational Image. pixabay

Americans love their pets.

Almost half of all U.S. households have a dog, according to the American Pet Products Association.

More millennials — people roughly between the ages of 23 and 38 — own pets than anyone else, and are willing to spend more money on their furry friends than any previous generation. Pet owners pay out about $70 billion a year on their pets, according to the APPA, and that includes hiring dog walkers to take the animals for a stroll while their owners are at work, away, or otherwise occupied.

The dog walking industry brought in $1 billion dollars in 2018, according to market research firm IBISWorld.

Also Read- India’s Thermal Coal Imports Can Expect 10% Increase this Year

Heather Rice runs her own dog-walking firm in Northern Virginia. VOA recently spent a day on the job with her. (VOA)

Next Story

India: Boost to Biocon’s Biosimilar Business as Bengaluru Units Get European Nod

The international certification would enable the company to address the patients' needs

0
Biocon, Business, Bengaluru
In March, the European regulator (EMA) inspected the twin facilities where a range of bio-similars are manufactured. Pixabay

The European Medicines Agency (EMA) has certified the Biocon drug product and substance facilities in the city’s southern suburb for good manufacturing practice.

“We have received a certificate from EMA for the good manufacturing practice compliance by our biological drug product and substance facilities at Bengaluru,” said the city-based leading biotech firm in a statement on Saturday.

Biocon, Business, Bengaluru
The European Medicines Agency (EMA) has certified the Biocon drug product. Pixabay

In March, the European regulator (EMA) inspected the twin facilities where a range of bio-similars are manufactured. “It was a surveillance inspection of our facilities and a pre-approval inspection of our additional manufacturing line,” said the statement.

Also Read- Greenland Lost More than 2 Billion Tons of Ice, with over 40% of Country Experiencing Unusual Melting

The international certification would enable the company to address the patients’ needs in the European Union (EU) markets and enhance access to its bio-similars, said a Biocon’s spokesperson in the statement. (IANS)

Next Story